Watch this recorded webinar to learn about the regulatory frameworks for regenerative medicine in Japan, as well as opportunities for collaboration with the Forum for Innovative Regenerative Medicine (FIRM).
Japan is a world leading country in the research field of regenerative medicine.
In November 2014, the regenerative medicine safety law came into force and has built momentum for practical medicine under the Pharmaceutical and Medical Device Affairs Law in Japan. The new legal framework is expected to provide an impetus to the commercialisation of regenerative medicine products in Japan.
The Forum for Innovative Regenerative Medicine (FIRM) is a business community organisation in Japan – with over 100 member corporations – that has been playing a vital role in working with other industry groups, government and universities to promote regenerative medicine as a new medicine and a new industrial field, as well as ensuring that research results are quickly commercialised in a safely and timely manner.
(For more information about FIRM: http://firm.or.jp/en)
In this webinar Mr. Hajime Miyamoto, the Vice Chairman of Steering Committee, FIRM, talks about the overview of new regulatory frameworks for regenerative medicine in Japan, the transition to industrialisation of regenerative medicine, and the activities of FIRM, including possible future collaborations in the field of regenerative medicine.
About the Speaker
Mr. Hajime Miyamoto is a member of the Board and Head of Administration Division of Medinet Co., Ltd., a company proccessing immuno-cells for medical institutions who provide cell therapy. Before he joined Medinet, he spent 24 years at Fujitsu Ltd. in the area of software, legal and policy promotion. He has obtained his BS degree from the University of San Francisco. Last year, he was appointed as the Vice Chairman of the Steering Committee of Forum for Innovative Regenerative Medicine (FIRM), the industrial association in Japan.
Benefits of Watching
- Explains recent regulatory developments of regenerative medicine in Japan.
- Provides an opportunity to understand the Japanese regenerative medicine market, including areas of business opportunities for UK companies and future collaboration opportunities for UK universities and research institutions.
Find out whether your products are suitable for the Japanese market by Sending Us Your Enquiry.
This webinar was recorded on 9 March 2015.